Page last updated: 2024-12-07
n-desmethylrufloxacin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
N-desmethylrufloxacin: structure given in first source; metabolite of rufloxacin found in urine of Rhesus monkey Macaca mulatta [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 127796 |
| CHEMBL ID | 330932 |
| SCHEMBL ID | 6301660 |
| MeSH ID | M0200197 |
Synonyms (10)
| Synonym |
|---|
| mf 922 |
| n-desmethylrufloxacin |
| CHEMBL330932 |
| mf-922 |
| 101337-87-5 |
| 7h-pyrido(1,2,3-de)-1,4-benzothiazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-7-oxo-10-(1-piperazinyl)- |
| SCHEMBL6301660 |
| DTXSID80143863 |
| 7-fluoro-10-oxo-6-piperazin-1-yl-4-thia-1-azatricyclo[7.3.1.05,13]trideca-5(13),6,8,11-tetraene-11-carboxylic acid |
| 8-fluoro-6-oxo-9-piperazin-1-yl-2,3-dihydro-6h-1-thia-3a-aza-phenalene-5-carboxylic acid |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " An example of a pharmacokinetic study of rufloxacin and its metabolites in monkeys is shown." | ( High-performance liquid chromatography and preliminary pharmacokinetics of rufloxacin and its metabolites, N-desmethylrufloxacin and rufloxacinsulfoxide, in urine of rhesus monkey Macaca mulatta. Imbimbo, BP; Peeters, A; van den Biggelaar-Martea, M; Vree, TB, 1992) | 0.5 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| "The in vitro activity of rufloxacin, alone and in combination with its metabolite (MF 922) against common respiratory and urinary tract pathogens and anaerobes was assessed." | ( Bactericidal activity, morphological alterations, and synergistic interactions of rufloxacin, a new fluoroquinolone, alone and in combination with its N-desmethylate D derivative (MF 922). Debbia, EA; Marchese, A; Pesce, A; Schito, GC, ) | 0.13 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (9)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID14382 | Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg | 1993 | Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22 | Quinolinecarboxylic acids. 3. Synthesis and antibacterial evaluation of 2-substituted-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de] [1,4]benzothiazine-6-carboxylic acids related to rufloxacin. |
| AID165055 | In vitro antibacterial activity against clinical isolates of Pseudomonas aeruginosa 2437 (gram negative) by agar dilution assay. | 1987 | Journal of medicinal chemistry, Mar, Volume: 30, Issue:3 | Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids. |
| AID14381 | Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg | 1993 | Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22 | Quinolinecarboxylic acids. 3. Synthesis and antibacterial evaluation of 2-substituted-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de] [1,4]benzothiazine-6-carboxylic acids related to rufloxacin. |
| AID206437 | In vitro antibacterial activity against clinical isolates of Staphylococcus aureus 18773 (gram-positive) by agar dilution assay. | 1987 | Journal of medicinal chemistry, Mar, Volume: 30, Issue:3 | Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids. |
| AID14380 | Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg | 1993 | Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22 | Quinolinecarboxylic acids. 3. Synthesis and antibacterial evaluation of 2-substituted-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de] [1,4]benzothiazine-6-carboxylic acids related to rufloxacin. |
| AID68201 | In vitro antibacterial activity against clinical isolates of Enterobacter cloacae 041 (gram negative) by agar dilution assay. | 1987 | Journal of medicinal chemistry, Mar, Volume: 30, Issue:3 | Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids. |
| AID70947 | In vitro antibacterial activity against clinical isolates of Escherichia coli 15 (gram negative) by agar dilution assay. | 1987 | Journal of medicinal chemistry, Mar, Volume: 30, Issue:3 | Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids. |
| AID96264 | In vitro antibacterial activity against clinical isolates of Klebsiella pneumoniae-4 (gram negative) by agar dilution assay. | 1987 | Journal of medicinal chemistry, Mar, Volume: 30, Issue:3 | Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids. |
| AID162914 | In vitro antibacterial activity against clinical isolates of Proteus morganii 27 (gram negative) by agar dilution assay. | 1987 | Journal of medicinal chemistry, Mar, Volume: 30, Issue:3 | Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (4)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.81
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.81) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||